search
Back to results

Endovascular Repair of Descending Thoracic Aortic Aneurysms

Primary Purpose

Aortic Aneurysm, Thoracic

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System
Sponsored by
Stanford University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Aneurysm, Thoracic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient is a candidate for repair of a descending thoracic aortic aneurysm.
  2. Patient has one or more of the following:

    • Descending thoracic aneurysm, 5 cm in diameter or greater with proximal and distal neck suitable for stent graft placement.
    • Aneurysm is 4-5 cm in diameter but has increased in size by 0.5 cm in last 6 months.
    • Maximum diameter of aneurysm exceeds one and one-half times the transverse dimension of an adjacent normal aortic segment.
    • Post-traumatic pseudoaneurysm
    • Post-surgical pseudoaneurysm
    • Saccular aneurysm
    • Contained rupture
    • Penetrating ulcer
  3. Patient's vascular dimensions must be in the range that can be safely treated with the stent graft and extensions available to the physician at the time of the procedure.
  4. Patient has patent iliac or femoral arteries or acceptable retroperitoneal access via the abdominal aorta that allow endovascular access to the aneurysmal site with a 23F delivery catheter, typically used with a 25F introducer sheath
  5. Patient has a non-aneurysmal proximal and distal aortic neck diameter between 25 and 36 mm.
  6. Patient is American Society of Anesthesiology (ASA) grade 1 through 4.
  7. Patient has a stage of disease or condition where there is no comparable or satisfactory alternative device or therapy available for treatment; or the patient has an immediately life-threatening disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment.
  8. Patient is able and willing to comply with 1 month, 6 month, and 1 year follow-up, and willing to comply with annual post-treatment follow-up requirements thereafter.
  9. Patient or patient's legal representative understands and has signed an Informed Consent.

Exclusion Criteria:

  1. The stent graft would have to be positioned such that there would be no flow to an artery, major branch artery or major branch arteries which supply the spinal cord.
  2. The patient has congenital abnormalities in which the placement of the stent graft will cause occlusion of major arterial flow. Such abnormalities should be evaluated prior to treatment.
  3. Patient is pregnant.
  4. Patient is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
  5. Patient has connective tissue disease.
  6. Patient has a hypercoagulability disorder.
  7. Patient is in acute renal failure.
  8. Patient has active systemic infection.
  9. Patient is less than 18 years old.
  10. Patient has less than a one-year life expectancy.
  11. Patient is participating in another research study involving an investigational agent for the treatment of Descending Thoracic Aortic Aneurysms.
  12. Patient has other medical, social or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
  13. Patient is unwilling or unable to return for or comply with follow-up visit schedules.

Sites / Locations

  • Stanford University School of Medicine

Outcomes

Primary Outcome Measures

Stent graft migration
Vessel Dissection or perforation
Stent graft occlusion
Collateral vessel occlusion
Aneurysm rupture
Aneurysm exclusion

Secondary Outcome Measures

Technical success
Patency

Full Information

First Posted
December 4, 2007
Last Updated
October 5, 2020
Sponsor
Stanford University
search

1. Study Identification

Unique Protocol Identification Number
NCT00802984
Brief Title
Endovascular Repair of Descending Thoracic Aortic Aneurysms
Official Title
Endovascular Treatment of Thoracic Aortic Aneurysms Using the TALENT Stent Graft System
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
January 2002 (Actual)
Primary Completion Date
December 2005 (Actual)
Study Completion Date
December 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stanford University

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether the system is safe and effective for the intended use of treating descending thoracic aortic aneurysms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Aneurysm, Thoracic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
29 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System
Primary Outcome Measure Information:
Title
Stent graft migration
Title
Vessel Dissection or perforation
Title
Stent graft occlusion
Title
Collateral vessel occlusion
Title
Aneurysm rupture
Title
Aneurysm exclusion
Secondary Outcome Measure Information:
Title
Technical success
Title
Patency

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is a candidate for repair of a descending thoracic aortic aneurysm. Patient has one or more of the following: Descending thoracic aneurysm, 5 cm in diameter or greater with proximal and distal neck suitable for stent graft placement. Aneurysm is 4-5 cm in diameter but has increased in size by 0.5 cm in last 6 months. Maximum diameter of aneurysm exceeds one and one-half times the transverse dimension of an adjacent normal aortic segment. Post-traumatic pseudoaneurysm Post-surgical pseudoaneurysm Saccular aneurysm Contained rupture Penetrating ulcer Patient's vascular dimensions must be in the range that can be safely treated with the stent graft and extensions available to the physician at the time of the procedure. Patient has patent iliac or femoral arteries or acceptable retroperitoneal access via the abdominal aorta that allow endovascular access to the aneurysmal site with a 23F delivery catheter, typically used with a 25F introducer sheath Patient has a non-aneurysmal proximal and distal aortic neck diameter between 25 and 36 mm. Patient is American Society of Anesthesiology (ASA) grade 1 through 4. Patient has a stage of disease or condition where there is no comparable or satisfactory alternative device or therapy available for treatment; or the patient has an immediately life-threatening disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment. Patient is able and willing to comply with 1 month, 6 month, and 1 year follow-up, and willing to comply with annual post-treatment follow-up requirements thereafter. Patient or patient's legal representative understands and has signed an Informed Consent. Exclusion Criteria: The stent graft would have to be positioned such that there would be no flow to an artery, major branch artery or major branch arteries which supply the spinal cord. The patient has congenital abnormalities in which the placement of the stent graft will cause occlusion of major arterial flow. Such abnormalities should be evaluated prior to treatment. Patient is pregnant. Patient is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta. Patient has connective tissue disease. Patient has a hypercoagulability disorder. Patient is in acute renal failure. Patient has active systemic infection. Patient is less than 18 years old. Patient has less than a one-year life expectancy. Patient is participating in another research study involving an investigational agent for the treatment of Descending Thoracic Aortic Aneurysms. Patient has other medical, social or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment. Patient is unwilling or unable to return for or comply with follow-up visit schedules.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher K Zarins, MD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jason T Lee, MD
Facility Information:
Facility Name
Stanford University School of Medicine
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Endovascular Repair of Descending Thoracic Aortic Aneurysms

We'll reach out to this number within 24 hrs